Media & Press

Ron Lanton III, Esq., Senior Partner at Lanton, Lanton & Sosa Law, provides legal and policy commentary to national and international news outlets covering healthcare, pharmaceuticals, biotechnology and government affairs.

Selected independent coverage

Fierce Biotech | November 10, 2026

‘Flying blind’: Why experts fear Treasury’s China biotech investment crackdown will backfire

Commentary on proposed outbound investment restrictions, pharmaceutical licensing, joint ventures and biotech financing.

Pink Sheet | October 21, 2026

USTR Investigation Into German Drug Pricing: Who Could Be Next?

Analysis of U.S. trade policy and potential implications for European pharmaceutical markets. Related LL&S analysis.

Reuters | September 22, 2026

European drugmakers call for faster trials, more spending to compete with US, China

Commentary on pharmaceutical investment, launch decisions and U.S. policy.

Reuters | March 31, 2026

Drugmakers delay some European launches with a wary eye on Trump’s pricing policies

Discussion of drug pricing uncertainty, market access and investor considerations.

APM Market Access

Publisher coverage: U.S. most-favored-nation drug pricing and launch sequencing

Leerink Partners

What Happens When Drug Pricing Meets Trade Policy? A Conversation with Ron Lanton

Industry publications and interviews

Explore Ron's BioPharm International author page, The Ron Lanton Report and the firm's Insights.

Media inquiries

For interviews or legal commentary, contact Lanton, Lanton & Sosa Law.